Neogen Chemicals Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ad51werncwaxibovofln8ap1.pdf

Key Takeaways


Base Business: Demand & Recovery

Dr. Harin Kanani: "We had an option either to wait longer for prices to recover. But since we didn't see serious price recovery happening immediately, we decided to go ahead and sell at what is today's market price."

Battery Chemicals: Build-out & Timelines

Dr. Harin Kanani: "Therefore, when we offer a salt, the question that remains is that instead of importing from China, I have to import from India. That is why we are not making a very big change from what is already being done. That is the reason why salts are easier to export to the international market whereas electrolytes are usually made locally."

Margins & Profitability

Dr. Harin Kanani: "The basis for our assumption is that we are looking at, if we are doing an investment, we are taking the risk, if we are the first mover and to be able to justify the risk and the investment, this is the bare minimum that we need."

CSM & the Pipeline

Dr. Harin Kanani: "While the number of relationships have increased, the number of molecules have increased, but still we don't have a very good clarity at least in the first half of the next financial year."

India Battery Ecosystem & Competitive Position

Dr. Harin Kanani: "For cathode we will move ahead only when we have a very firm, binding contract or a kind of joint development or a joint plan. Some such situation is only when we will basically venture into a cathode area."

Balance Sheet & Funding


Guidance & Commitments

CommitmentSpecificsTimeline
Battery sales startInternal target to begin some battery salesBefore March 2024
Dahej electrolyte facility commissioned2,000 MT facility ready for customer trialsEnd of Q4 FY24
Electrolyte salt customer approvalsApprovals start coming through; revenue beginsEnd of Q4 FY24 to early Q1 FY25
Pakhajan 30 KTA plant construction startPermissions expected, construction beginsMarch-April 2024
Pakhajan 30 KTA plant operationalPlant commissionedH2 FY26, around December 2025 (±1 quarter)
Salt capacity phased commissioning1,000 MT, then 1,500 MT, then 2,500 MT onlineQ2/Q3 FY25 through end of Q4 FY25
Additional salt capacity3,000 MT addedFY26
Inventory impact normalizedHigh-cost inventory impact fully behindQ1 FY25 onwards
Base business EBITDA improvementBetter product selection, full utilizationFY26
Brownfield SOC expansionRemaining 29 m³ commissioned depending on business needsDuring FY25
Cathode entryOnly with firm binding contract or joint development planCondition-based, no timeline

Key Metrics

MetricQ3 FY24
Consolidated revenue₹164.4 cr, down 12% YoY
Standalone revenue₹167.4 cr, vs ₹186.3 cr YoY
Consolidated EBITDA₹20.4 cr, impacted by higher employee costs, Neogen Ionics expenses, and BuLi Chem inventory liquidation
Standalone EBITDA₹25.8 cr, vs ₹30.1 cr YoY
Consolidated PAT₹1.1 cr, includes higher finance costs, depreciation, and one-time tax charge on transition to new tax regime
Standalone PAT₹5.8 cr, vs ₹14.7 cr YoY
Organic Chemicals revenue₹129 cr, down 5% YoY; would have been higher by ₹12 cr adjusting for bromine and RM price drop
Inorganic Chemicals revenue₹35 cr, down 30% YoY; would have been higher by ₹23 cr adjusting for lithium raw material price fall
Domestic to export mix78% to 22%
CSM business contribution14% to 15% of revenue
Advanced intermediate and CSM combined contribution~30% of revenue, vs target of 40%
Inventory loss from lithium price fluctuation₹4.5 cr to ₹5 cr on BuLi Chem, ₹2.5 cr on Neogen
Gross long-term debt~₹150 cr; working capital ₹200-250 cr
Aggregate CAPEX for FY24 and beyond capacitiesclose to ₹1,500 cr, with peak revenue potential of ₹2,500 cr to ₹2,950 cr depending on lithium prices
Electrolyte salt capacity expansion target at Dahej SEZ2,500 metric tons in phases during FY25, up from earlier 1,000 metric tons plan